Publicacións en colaboración con investigadores/as de Hospital Son Llàtzer (3)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

2022

  1. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93

2016

  1. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1